Electromed (NYSE:ELMD) Stock Rating Upgraded by B. Riley

Electromed (NYSE:ELMD) was upgraded by analysts at B. Riley to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Separately, StockNews.com cut Electromed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday.

Electromed Stock Performance

ELMD stock opened at $28.63 on Wednesday. The stock’s 50 day moving average price is $31.40 and its 200 day moving average price is $25.17. The firm has a market cap of $245.07 million, a P/E ratio of 38.17 and a beta of 0.33. Electromed has a 1 year low of $13.74 and a 1 year high of $35.56.

Insiders Place Their Bets

In other news, Director Kathleen Skarvan sold 38,954 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $29.28, for a total transaction of $1,140,573.12. Following the completion of the transaction, the director now owns 32,622 shares of the company’s stock, valued at $955,172.16. This represents a 54.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Andrew Summers sold 12,731 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $29.98, for a total transaction of $381,675.38. Following the completion of the sale, the director now directly owns 165,755 shares in the company, valued at $4,969,334.90. This represents a 7.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 77,788 shares of company stock valued at $2,326,350. Company insiders own 14.00% of the company’s stock.

Hedge Funds Weigh In On Electromed

A number of large investors have recently modified their holdings of ELMD. Arrowstreet Capital Limited Partnership increased its position in Electromed by 261.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock worth $3,386,000 after purchasing an additional 82,839 shares in the last quarter. Hunter Associates Investment Management LLC raised its stake in shares of Electromed by 12.3% in the 3rd quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock valued at $2,199,000 after acquiring an additional 11,250 shares during the period. Northern Trust Corp lifted its holdings in shares of Electromed by 14.1% during the 4th quarter. Northern Trust Corp now owns 65,350 shares of the company’s stock valued at $1,931,000 after acquiring an additional 8,086 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Electromed during the 4th quarter worth $1,760,000. Finally, Susquehanna International Group LLP increased its holdings in Electromed by 121.8% in the 4th quarter. Susquehanna International Group LLP now owns 56,726 shares of the company’s stock valued at $1,676,000 after purchasing an additional 31,148 shares in the last quarter. 40.82% of the stock is currently owned by hedge funds and other institutional investors.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.